Mary Ann Liebert Inc., publishers has announced the launch of Psychedelic Medicine, an influential and dynamic peer-reviewed journal supporting the growing influential research and clinical applications in this pivotal field. Publishing online and in print with open access options, Psychedelic Medicine will provide an authoritative, high-profile forum for groundbreaking original research papers, review articles, captivating front matter, debate, and commentary. A preview issue of the Journal is planned for late 2022.
Psychedelic substances, clinically authorized and regulated by practitioners to treat psychological disorders, are rapidly moving into the mainstream as clinical research programs and legalization/decriminalization measures accelerate in the United States, United Kingdom, and Europe. Psychedelic substances undergoing research in clinical studies include ketamine, psilocybin, Ayahuasca, MDMA, and DMT. Patients and clinicians are increasingly optimistic about the efficacy of psychedelic drugs as an alternative or supplement to traditionally manufactured pharmaceuticals to treat depression, anxiety, addiction, PTSD, anger and aggression, and other psychological conditions. Clinical studies have supported claims that, when administered responsibly, psychedelic treatments are generally safe, effective, and less likely to induce long-term dependencies than mainstream psychiatric medications.
Psychedelic Medicine will provide rapid, fair peer-review and welcomes original research papers on every aspect of psychedelic medicine in clinical settings, including basic research, translational, clinical, and medical applications.Click here to read the original press release.